Idelalisib: first global approval.
Markham A.
Drugs · review; journal article · DOI 10.1007/s40265-014-0285-6 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för idelalisib. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
13 träffarIdelalisib approved for trio of blood cancers.
Författaruppgift saknas
Cancer Discov · news · DOI 10.1158/2159-8290.cd-nb2014-122Idelalisib for the treatment of chronic lymphocytic leukemia.
Khan M, Saif A, Sandler S, Mirrakhimov AE.
ISRN Oncol · research-article; review; journal article · DOI 10.1155/2014/931858Idelalisib has activity in mantle cell lymphoma.
Författaruppgift saknas
Cancer Discov · journal article · DOI 10.1158/2159-8290.cd-rw2014-072Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE.
Blood · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1182/blood-2013-11-538546Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR.
Blood · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1182/blood-2013-11-535047A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND.
Blood · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1182/blood-2013-11-537555Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
Lopez JP, Jimeno A.
Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2014.50.2.2104040A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE.
Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.1484Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O'Brien SM.
N Engl J Med · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1315226PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, Flinn IW, Flowers CR, Martin P, Viardot A, Blum KA, Goy AH, Davies AJ, Zinzani PL, Dreyling M, Johnson D, Miller LL, Holes L, Li D, Dansey RD, Godfrey WR, Salles GA.
N Engl J Med · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa1314583Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry.
Veeraraghavan S, Thappali S, Viswanadha S, Nalla S, Chennupati S, Golla M, Vakkalanka S, Rangasamy M.
J Chromatogr B Analyt Technol Biomed Life Sci · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jchromb.2014.01.001The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA.
PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0083830